6
|
Goga A, Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Anderton B, Mahieu C, Eyob H, Krings G, Nomura DK. Abstract PD3-05: Inhibition of fatty-acid oxidation as a therapy for triple-negative breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-pd3-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Expression of the oncogenic transcription factor MYC is disproportionately elevated in triple-negative breast cancer (TNBC) compared to estrogen, progesterone and/or human epidermal growth factor 2 receptor-positive (RP) breast tumors. We and others have shown that MYC alters metabolism during tumorigenesis. However, the role of MYC in TNBC metabolism remains largely unexplored. We hypothesized that pharmacologic inhibition of MYC-driven metabolic pathways may serve as a therapeutic strategy for this clinically challenging subtype of breast cancer. Using an unbiased metabolomics approach, we identified fatty acid oxidation intermediates as dramatically up-regulated in MYC-driven models of TNBC. A lipid metabolism gene signature was identified in patients with TNBC in the TCGA and multiple other clinical datasets, implicating fatty acid oxidation as a deregulated pathway critical for TNBC metabolism. We find that MYC-overexpressing TNBC, including transgenic models and patient-derived xenografts (PDX), display increased bioenergetic reliance upon fatty-acid oxidation (FAO). Pharmacologic inhibition of FAO catastrophically decreases energy metabolism of MYC over-expressing breast cancer, blocks growth of a MYC-driven transgenic TNBC model and MYC-overexpressing patient-derived xenografts. In vivo inhibition of FAO induced proliferation arrest and increased cell death in PDX models of TNBC. Our results demonstrate that inhibition of FAO is a novel therapeutic strategy against TNBCs that over-express MYC.
Citation Format: Goga A, Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Anderton B, Mahieu C, Eyob H, Krings G, Nomura DK. Inhibition of fatty-acid oxidation as a therapy for triple-negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr PD3-05.
Collapse
Affiliation(s)
- A Goga
- University of California, San Francisco; University of California, Berkeley
| | - R Camarda
- University of California, San Francisco; University of California, Berkeley
| | - AY Zhou
- University of California, San Francisco; University of California, Berkeley
| | - RA Kohnz
- University of California, San Francisco; University of California, Berkeley
| | - S Balakrishnan
- University of California, San Francisco; University of California, Berkeley
| | - B Anderton
- University of California, San Francisco; University of California, Berkeley
| | - C Mahieu
- University of California, San Francisco; University of California, Berkeley
| | - H Eyob
- University of California, San Francisco; University of California, Berkeley
| | - G Krings
- University of California, San Francisco; University of California, Berkeley
| | - DK Nomura
- University of California, San Francisco; University of California, Berkeley
| |
Collapse
|
10
|
Vekhoff P, Halby L, Oussedik K, Dallavalle S, Merlini L, Mahieu C, Lansiaux A, Bailly C, Boutorine A, Pisano C, Giannini G, Alloatti D, Arimondo PB. Optimized Synthesis and Enhanced Efficacy of Novel Triplex-Forming Camptothecin Derivatives Based on Gimatecan. Bioconjug Chem 2009; 20:666-72. [DOI: 10.1021/bc800494y] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Pierre Vekhoff
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Ludovic Halby
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Kahina Oussedik
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Sabrina Dallavalle
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Lucio Merlini
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Christine Mahieu
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Amélie Lansiaux
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Christian Bailly
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Alexandre Boutorine
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Claudio Pisano
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Giuseppe Giannini
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Domenico Alloatti
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| | - Paola B. Arimondo
- CNRS UMR5153, Muséum National d’Histoire Naturelle USM0503, and INSERM U565, 43 rue Cuvier, 75231 Paris cedex 05, France, UPMC, Paris 75005, France, DISMA, Università di Milano, via Celoria 2, 20133 Milano, Italy, INSERM U-837, COL, IRCL, Place Verdun, 59045 Lille, France, and Sigma-tau Industrie Farmaceutiche Riunite SpA, Pomezia, Italy
| |
Collapse
|